HUP0202729A3 - Compositions for parenteral use of estramustine phosphate and amino acids - Google Patents
Compositions for parenteral use of estramustine phosphate and amino acidsInfo
- Publication number
- HUP0202729A3 HUP0202729A3 HU0202729A HUP0202729A HUP0202729A3 HU P0202729 A3 HUP0202729 A3 HU P0202729A3 HU 0202729 A HU0202729 A HU 0202729A HU P0202729 A HUP0202729 A HU P0202729A HU P0202729 A3 HUP0202729 A3 HU P0202729A3
- Authority
- HU
- Hungary
- Prior art keywords
- compositions
- amino acids
- parenteral use
- estramustine phosphate
- estramustine
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title 1
- 229960004750 estramustine phosphate Drugs 0.000 title 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9921960.2A GB9921960D0 (en) | 1999-09-16 | 1999-09-16 | Formulations for parenteral use of estramustine phosphate and amino acids |
| PCT/EP2000/008983 WO2001019372A1 (en) | 1999-09-16 | 2000-09-13 | Formulations for parenteral use of estramustine phosphate and amino acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0202729A2 HUP0202729A2 (hu) | 2003-01-28 |
| HUP0202729A3 true HUP0202729A3 (en) | 2003-12-29 |
Family
ID=10861070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202729A HUP0202729A3 (en) | 1999-09-16 | 2000-09-13 | Compositions for parenteral use of estramustine phosphate and amino acids |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1214078B1 (hu) |
| JP (1) | JP2003509372A (hu) |
| KR (1) | KR20020059592A (hu) |
| CN (1) | CN1373667A (hu) |
| AT (1) | ATE283053T1 (hu) |
| AU (1) | AU779922B2 (hu) |
| BR (1) | BR0014071A (hu) |
| CA (1) | CA2384726A1 (hu) |
| CZ (1) | CZ2002945A3 (hu) |
| DE (1) | DE60016252D1 (hu) |
| EA (1) | EA005311B1 (hu) |
| GB (1) | GB9921960D0 (hu) |
| HK (1) | HK1048948A1 (hu) |
| HU (1) | HUP0202729A3 (hu) |
| IL (1) | IL148513A0 (hu) |
| MX (1) | MXPA02002854A (hu) |
| NO (1) | NO20021302L (hu) |
| NZ (1) | NZ518182A (hu) |
| PL (1) | PL354746A1 (hu) |
| SK (1) | SK3442002A3 (hu) |
| WO (1) | WO2001019372A1 (hu) |
| ZA (1) | ZA200202689B (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1318689B1 (it) * | 2000-09-12 | 2003-08-27 | Pharmacia & Upjohn Spa | Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| EP1893159B1 (en) | 2005-06-17 | 2015-09-30 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents |
| WO2008050836A1 (en) * | 2006-10-25 | 2008-05-02 | Ajinomoto Co., Inc. | Agent for ameliorating adverse side-effect of chemotherapeutic agent |
| GB2471065A (en) * | 2009-06-10 | 2010-12-22 | Univ Sheffield | Modulator of claspin for treatment of cell proliferative disorder |
| WO2011094814A1 (en) | 2010-02-05 | 2011-08-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| WO2011120084A1 (en) | 2010-03-30 | 2011-10-06 | Phosphagenics Limited | Transdermal delivery patch |
| US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
| EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
| CN107530291A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 双重负载的脂质体药物制剂 |
| ES2981002T3 (es) | 2015-12-09 | 2024-10-04 | Avecho Biotechnology Ltd | Formulación farmacéutica |
| AU2017381395A1 (en) | 2016-12-21 | 2019-06-20 | Phosphagenics Limited | Process |
| WO2024102547A1 (en) * | 2022-11-11 | 2024-05-16 | Michael Farber | Anhydrous compositions of polysorbates and cyclodextrins for shelf stable drug combinations with macrocyclic lactone complexes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807572A (en) * | 1988-02-18 | 1998-09-15 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度ｔｃｆ製剤 |
| US5785976A (en) * | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
-
1999
- 1999-09-16 GB GBGB9921960.2A patent/GB9921960D0/en not_active Ceased
-
2000
- 2000-09-13 CN CN00812880A patent/CN1373667A/zh active Pending
- 2000-09-13 HU HU0202729A patent/HUP0202729A3/hu unknown
- 2000-09-13 CZ CZ2002945A patent/CZ2002945A3/cs unknown
- 2000-09-13 PL PL00354746A patent/PL354746A1/xx not_active Application Discontinuation
- 2000-09-13 CA CA002384726A patent/CA2384726A1/en not_active Abandoned
- 2000-09-13 DE DE60016252T patent/DE60016252D1/de not_active Expired - Lifetime
- 2000-09-13 BR BR0014071-6A patent/BR0014071A/pt not_active IP Right Cessation
- 2000-09-13 NZ NZ518182A patent/NZ518182A/en unknown
- 2000-09-13 MX MXPA02002854A patent/MXPA02002854A/es unknown
- 2000-09-13 EA EA200200368A patent/EA005311B1/ru not_active IP Right Cessation
- 2000-09-13 AT AT00967673T patent/ATE283053T1/de not_active IP Right Cessation
- 2000-09-13 KR KR1020027003380A patent/KR20020059592A/ko not_active Withdrawn
- 2000-09-13 EP EP00967673A patent/EP1214078B1/en not_active Expired - Lifetime
- 2000-09-13 SK SK344-2002A patent/SK3442002A3/sk unknown
- 2000-09-13 HK HK03101212.7A patent/HK1048948A1/zh unknown
- 2000-09-13 JP JP2001523004A patent/JP2003509372A/ja not_active Withdrawn
- 2000-09-13 AU AU77762/00A patent/AU779922B2/en not_active Ceased
- 2000-09-13 IL IL14851300A patent/IL148513A0/xx unknown
- 2000-09-13 WO PCT/EP2000/008983 patent/WO2001019372A1/en not_active Ceased
-
2002
- 2002-03-15 NO NO20021302A patent/NO20021302L/no not_active Application Discontinuation
- 2002-04-05 ZA ZA200202689A patent/ZA200202689B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2384726A1 (en) | 2001-03-22 |
| NO20021302D0 (no) | 2002-03-15 |
| NO20021302L (no) | 2002-04-24 |
| NZ518182A (en) | 2004-02-27 |
| AU779922B2 (en) | 2005-02-17 |
| GB9921960D0 (en) | 1999-11-17 |
| SK3442002A3 (en) | 2002-09-10 |
| EP1214078B1 (en) | 2004-11-24 |
| MXPA02002854A (es) | 2003-07-21 |
| HUP0202729A2 (hu) | 2003-01-28 |
| HK1048948A1 (zh) | 2003-04-25 |
| EA200200368A1 (ru) | 2002-10-31 |
| CN1373667A (zh) | 2002-10-09 |
| JP2003509372A (ja) | 2003-03-11 |
| BR0014071A (pt) | 2002-05-21 |
| IL148513A0 (en) | 2002-09-12 |
| ZA200202689B (en) | 2003-10-29 |
| EP1214078A1 (en) | 2002-06-19 |
| ATE283053T1 (de) | 2004-12-15 |
| CZ2002945A3 (cs) | 2002-07-17 |
| KR20020059592A (ko) | 2002-07-13 |
| EA005311B1 (ru) | 2004-12-30 |
| AU7776200A (en) | 2001-04-17 |
| WO2001019372A1 (en) | 2001-03-22 |
| DE60016252D1 (de) | 2004-12-30 |
| PL354746A1 (en) | 2004-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL148933A0 (en) | Compositions and methods for tumor-targeted delivery of effector molecules | |
| IL146575A0 (en) | Compositions of a-beta peptide and processes for producing same | |
| PL344589A1 (en) | COMPOSITION COMPRISING β-HYDROXY-β-METHYLBUTYRIC ACID AND AT LEAST ONE AMINO ACID AND METHODS OF USE | |
| AU4205100A (en) | Methods and compositions for the treatment of pancreatitis | |
| HUP0101580A3 (en) | Pharmaceutical compositions capable of being gelled | |
| PL339660A1 (en) | Derivatives of amidocarboxylic acids | |
| AU7620200A (en) | Compositions and methods relating to the inhibition of casomorphin and gluteomorphin | |
| AU6968898A (en) | Antisense oligonucleotide compositions and methods for the modulation of activating protein | |
| PL335168A1 (en) | Compositions for and methods of reducing intracocular hypertension | |
| AU4133701A (en) | Methods and compositions for peptide synthesis | |
| HUP0103601A3 (en) | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof | |
| PL338144A1 (en) | Derivatives of dolastatin 15 | |
| PL330482A1 (en) | Novel amino acid derivatives and their application as thrombosin inhibitors | |
| AU6838501A (en) | Enzyme-catalyzed polyamides and compositions and processes of preparing and using the same | |
| HUP0202729A3 (en) | Compositions for parenteral use of estramustine phosphate and amino acids | |
| EP1180006A4 (en) | COMPOSITIONS AND METHODS FOR PREPARING SUCH COMPOSITIONS FROM LEPIDIA | |
| LT99141A (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide | |
| US5937715B1 (en) | Socket for fasteners of various sizes | |
| PL355811A1 (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h | |
| IL132516A0 (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide | |
| GB9921958D0 (en) | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins | |
| PL317853A1 (en) | Derivatives of amino acids | |
| IL147745A0 (en) | Formulations for parenteral use of estramustine phosphate and albumin | |
| EP1163340A4 (en) | COMPOSITIONS AND METHODS FOR MODIFYING GENE EXPRESSION | |
| EP0994715A4 (en) | DIFLUORONUCLEOSIDE-PHOSPHONIC ACIDS AND DERIVATIVES THEREOF |